Tempus AI to Acquire Personalis in $1.5B Deal; $16.25/sh, Stock-Heavy Consideration

Tempus AI announced a definitive agreement to acquire Personalis for a $1.5 billion enterprise value with $16.25 per share consideration.

Key Highlights:

• Agreement structures two-step merger to make Personalis a direct, wholly-owned Tempus AI subsidiary.
• Consideration of $16.25 per Personalis share; total enterprise value $1.5 billion, net of Tempus AI’s stake.
• Deal is 100% stock consideration (floating exchange ratio, max 0.3356); Tempus AI may elect up to 50% cash.
• Closing expected late 2026 or early 2027, subject to Personalis shareholder and regulatory approvals.
• Personalis preliminary Q2 revenue $22.4M and 10,384 clinical tests (33% QoQ volume growth); transaction aims to scale MRD capabilities.

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.